Welcome to our dedicated page for Sensei Biotherapeutics news (Ticker: SNSE), a resource for investors and traders seeking the latest updates and insights on Sensei Biotherapeutics stock.
Sensei Biotherapeutics, Inc. (SNSE) is a clinical-stage biotechnology pioneer developing tumor microenvironment-activated immunotherapies. This page aggregates all material news and regulatory disclosures about the company's innovative TMAb™ platform and clinical programs.
Investors and industry observers will find timely updates on clinical trial progress, partnership announcements, financial disclosures, and scientific developments. Our curated collection ensures efficient tracking of key milestones in Sensei's quest to create conditionally active cancer therapies.
The repository includes earnings reports, FDA communications, research collaborations, and peer-reviewed publication highlights. All content is vetted for relevance to SNSE's core focus on overcoming immune suppression in solid tumors through pH-sensitive antibody engineering.
Bookmark this page for structured access to Sensei's evolving pipeline updates and corporate announcements. Regularly refreshed content supports informed decision-making about this innovative player in next-generation immuno-oncology.
Sensei Biotherapeutics announced the FDA's clearance of its IND application for SNS-101, a VISTA-blocking antibody, enabling a Phase 1/2 clinical trial for patients with solid tumors. This key milestone is expected to significantly impact cancer treatment. The trial will assess SNS-101's safety, tolerability, pharmacokinetics, and efficacy, both alone and combined with Regeneron’s Libtayo® (cemiplimab). The initial patient dosing is anticipated in mid-2023. Preclinical data suggest SNS-101's promising potential to inhibit tumor growth and enhance PD-1 blockade effects, while maintaining better pharmacokinetics and reducing cytokine release syndrome risk.
Sensei Biotherapeutics (Nasdaq: SNSE) presented new preclinical data on its SNS-103 program at the AACR Annual Meeting 2023, focusing on targeting CD39, an enzyme linked to an immunosuppressive tumor microenvironment. The data suggests that SNS-103, a conditionally active monoclonal antibody, selectively binds to CD39 in low pH conditions typical of tumors, potentially improving anti-tumor immunity by preserving extracellular ATP and inhibiting adenosine generation.
The poster presentation highlighted the selection of 8 antibodies for further optimization from a panel of 83, with a lead product candidate expected to be selected in 2023. This advancement could position Sensei favorably within the immuno-oncology sector.
Sensei Biotherapeutics (Nasdaq: SNSE) announced its participation in a panel discussion titled ‘Overcoming Resistance & Immunosuppression in Solid Tumors’ at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 20, 2023, at 3:00 p.m. ET. The company specializes in developing next-generation therapeutics for cancer patients through its TMAb™ platform.
Sensei's lead candidate is SNS-101, designed to inhibit T cell suppression in the tumor microenvironment. The company is also advancing SNS-102, targeting VSIG-4, and SNS-103, which targets ENTPDase1, also known as CD39. For more information, visit www.senseibio.com.
BOSTON, March 30, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics (Nasdaq: SNSE), an immuno-oncology firm, announced that its CEO, John Celebi, will participate in a panel on 'Novel Approaches in Immunotherapy' at the Cantor Fitzgerald's Future of Oncology Virtual Symposium on April 3rd at 10:00 a.m. ET.
Sensei Biotherapeutics focuses on developing next-generation therapeutics for cancer patients using its TMAb™ platform. The lead candidate is SNS-101, targeting VISTA in the tumor microenvironment. Other candidates include SNS-102 and SNS-103, which target VSIG-4 and ENTPDase1, respectively. For more details, visit www.senseibio.com.
FAQ
What is the current stock price of Sensei Biotherapeutics (SNSE)?
What is the market cap of Sensei Biotherapeutics (SNSE)?
